logo

For the Inventor, By the Inventor

Ecrosnes, France

Michel Perricaudet

This inventor holds 38 USPTO granted patents and 2 published patent applications and 2 EPO patents, primarily in Adenovirus Gene Therapy. Top assignees: Aventis Pharma S.a., Rhone-Poulenc Rorer S.a., Centre National De La Recherche Scientifique. Active years: 1998-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michel Perricaudet. Retrieved from https://idiyas.com/inventor/michel-perricaudet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 

% Patents Active = 86.8

 

Average Co-Inventor Count = 3.9

ph-index = 14

Forward Citations = 512(Granted Patents)


Location History:

  • Ouarville, FR (2000)
  • 28320 Ecrosnes, FR (2003)
  • Paris, FR (2002 - 2004)
  • Ecrignolles, FR (2004 - 2007)
  • Escrosnes, FR (2014)
  • Ecrosnes, FR (1998 - 2018)

Company Filing History:

goldMedal14 out of 377 
 
Aventis Pharma S.a.
 patents
silverMedal8 out of 247 
 
Rhone-Poulenc Rorer S.a.
 patents
bronzeMedal3 out of 5,383 
 
Centre National De La Recherche Scientifique
 patents
4. 2 out of 101 
 
Institut Gustave Roussy
 patents
5. 2 out of 159 
 
Transgene S.a.
 patents
6. 1 out of 1 
 
Gencell Sas
 patent
7. 1 out of 8 
 
Gencell, S.a.
 patents
8. 1 out of 1,217 
 
The United States of America as Represented by the Department of Health
 patents
9. 8 out of 834,453 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2018

Loading Chart...
Loading Chart...
Areas of Expertise:
Adenovirus Vectors
Gene Therapy
Antitumor Treatment
Recombinant Adenoviruses
Cytokines
Central Nervous System
Viral Particles
Adenoviral Vector
Therapeutic Products
Immunoprotective Gene
Dyslipoproteinemias
Replication Deficient
38 patents (USPTO):Explore Patents
1. 9862931 - Adenovirus vaccine vectors (2018-01-09),
2. 8642028 - Recombinant adenoviruses encoding the specific iodine transporter (NIS) (2014-02-04),
3. 7306793 - Defective recombinant adenoviruses expressing cytokines for antitumor treatment (2007-12-11),
4. RE39078 - Recombinant adenoviruses for gene therapy in cancers (2006-04-24),
5. 7033826 - Recombinant adenoviruses, use thereof for preparing AAVS, complementary cell line, and pharmaceutical compositions containing said adenoviruses (2006-04-25),
6. 6911199 - Targeted adenovirus vectors for delivery of heterologous genes (2005-06-28),
7. 6814962 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same (2004-11-09),
8. 6811774 - Defective recombinant adenoviruses expressing cytokines for antitumor treatment (2004-11-02),
9. RE38556 - Recombinant adeno viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias (2004-07-13),
10. 6756523 - Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain (2004-06-29),
11. 6743623 - Viral recombinant vectors for expression in muscle cells (2004-06-01),
12. 6696420 - Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein (2004-02-24),
13. 6685934 - Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF) (2004-02-03),
14. 6669942 - Defective adenoviruses including a therapeutic gene and an immunoprotectove gene (2003-12-30),
15. 6638502 - Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors (2003-10-28),

Title: Michel Perricaudet - Innovator in Gene Therapy and Vaccines

Introduction

Michel Perricaudet, hailing from Ecrosnes, France, is a prominent inventor in the field of gene therapy and vaccine development. With an impressive portfolio of 38 patents, Perricaudet has significantly contributed to the advancement of medical technologies that aim to strengthen immune responses and combat tumors.

Latest Patents

Among his notable recent inventions is a groundbreaking adenovirus vaccine vector. This invention relates to recombinant adenoviruses that display one or more heterologous epitopes on their fiber protein. These innovative recombinant adenoviruses are designed to be utilized as vaccines for eliciting immune responses against specific epitopes, even in individuals who possess pre-existing anti-Ad immunity. Additionally, he developed recombinant adenoviruses that encode the specific iodine transporter (NIS), which holds potential in the realm of gene therapy and tumor treatment.

Career Highlights

Michel Perricaudet has had an illustrious career, including pivotal roles at prominent pharmaceutical companies such as Aventis Pharma S.A. and Rhone-Poulenc Rorer S.A. His tenure in these organizations has allowed him to push the boundaries of medical research and innovation, with several noteworthy contributions leading to patented technologies.

Collaborations

Throughout his career, Perricaudet has collaborated with distinguished colleagues, including Emmanuelle Vigne and Patrice Yeh. These partnerships have fostered an environment of innovation and shared expertise that has propelled forward the objectives in gene therapy and vaccine development.

Conclusion

In conclusion, Michel Perricaudet stands out as a key figure in the fields of gene therapy and vaccines, with his extensive patent portfolio reflecting his dedication to advancing medical science. His inventive spirit and collaboration with other experts continue to pave the way for breakthroughs that have the potential to improve the lives of many individuals around the globe.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…